Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I-II Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive (High Grade) T-Cell Malignancies

NCT00035022 is registered in ClinicalTrials.gov with BioCryst Pharmaceuticals as lead sponsor.

NCT NCT00035022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00035022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I-II Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive (High Grade) T-Cell Malignancies
Lead sponsor
BioCryst Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2001
Completion date
March 31, 2004
Enrollment
71
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphocytic, lymphoma